Revumenib Approved for Relapsed/Refractory AML With Susceptible NPM1 Mutation
Expert Perspectives · Lyn Brook · 2025-10-30
The FDA has approved revumenib (Revuforj®, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for the treatment of relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients ages ≥1 year who have no satisfactory alternative treatment options.
Why This Approval Matters
This approval introduces the first menin inhibitor for patients with relapsed/refractory AML harboring a susceptible NPM1 mutation, addressing a high‑risk population with limited therapeutic options. By directly targeting the menin–KMT2A/HOX axis implicated in leukemogenesis, revumenib offers a mutation‑directed strategy with clinically meaningful remission and transfusion‑independence benefits.
Breaking Down the AUGMENT‑101 Trial
Efficacy was evaluated in AUGMENT-101 (NCT04065399), a phase 1/2, single‑arm, open‑label, multicenter study. Eligible patients had relapsed/refractory AML with a susceptible NPM1 mutation, confirmed by next‑generation sequencing or polymerase chain reaction of the last exon of NPM1.
Key efficacy end points included complete remission (CR), CR with partial hematologic recovery (CRh), duration of CR plus CRh, and conversion from transfusion dependence to independence. Results demonstrated:
- CR+CRh rate: 23.1%
- Median duration of CR+CRh: 4.5 months
Among 46 patients dependent on red blood cell and/or platelet transfusions at baseline, eight patients (17%) achieved transfusion independence during any 56‑day post‑baseline period.
Managing Adverse Events
The prescribing information includes warnings and precautions for differentiation syndrome, QTc interval prolongation and Torsades de Pointes, and embryo‑fetal toxicity.
Dosing and Administration
The recommended dosage of revumenib depends on patient weight and concomitant use of strong CYP3A4 inhibitors. Please refer to the prescribing information for specific dosing tables, adjustments, and administration guidance.